{"DataElement":{"publicId":"3028423","version":"1","preferredName":"Enzyme Activity Level Laboratory Procedure Performed Enzyme Deficiency Type","preferredDefinition":"A description of the enzyme deficiency that was evaluated for activity level.","longName":"3028406v1.0:3028408v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3028406","version":"1","preferredName":"Enzyme Activity Level Laboratory Procedure Performed","preferredDefinition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified._An action taken in pursuit of an objective; the state of being active._A position on a scale measuring intensity, quality, or amount._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.","longName":"3028403v1.0:2828214v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3028403","version":"1","preferredName":"Enzyme Activity Level Laboratory Procedure","preferredDefinition":"A protein that speeds up chemical reactions in the body.:The state of being active; any specific activity.:A position on a scale measuring intensity, quality, or amount.  (NCI):Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"C16554:C43431:C25554:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzyme","conceptCode":"C16554","definition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Activity","conceptCode":"C43431","definition":"An active process; excludes processes and mechanisms which fulfill biological functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Level","conceptCode":"C25554","definition":"A position on a scale measuring intensity, quality, or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8227DA85-CB57-0745-E040-BB89AD4364A8","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"ONEDATA","dateModified":"2010-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241241","version":"1","preferredName":"Performed","preferredDefinition":"Performed; carried out.","longName":"C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-8839-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8227DF17-B425-3912-E040-BB89AD435672","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2020-12-15","changeDescription":"2020-12-15 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3028408","version":"1","preferredName":"Enzyme Deficiency Type","preferredDefinition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified._In medicine, a shortage of a substance (such as a vitamin or mineral) needed by the body._Type; a subdivision of a particular kind of thing.","longName":"3028408v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other storage disease","valueDescription":"Other Lysosomal Storage Disease","ValueMeaning":{"publicId":"3028410","version":"1","preferredName":"Other Lysosomal Storage Disease","longName":"3028410","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes.  Signs and symtoms include hepatomegaly, splenomegaly, nervous sytem manifestations, skeletal abnormalities, and mental deterioration.  Representative examples, include Gaucher disease, Neimann-Pick disease, Wolman disease, and Fabry disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lysosomal Storage Disease","conceptCode":"C61250","definition":"A group of autosomal recessive or X-linked inherited metabolic disorders caused by defects in the function of the lysosomes. Signs and symptoms include hepatomegaly, splenomegaly, nervous system manifestations, skeletal abnormalities, and mental deterioration. Representative examples include Gaucher disease, Niemann-Pick disease, Wolman disease, and Fabry disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FB71-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8228AACA-FB8A-E06A-E040-BB89AD437846","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"ONEDATA","dateModified":"2010-03-19","deletedIndicator":"No"},{"value":"Acetyl-CoAlpha-glucosaminide acetyltransferase","valueDescription":"Mucopolysaccharidosis Type IIIC","ValueMeaning":{"publicId":"3005735","version":"1","preferredName":"Mucopolysaccharidosis Type IIIC","longName":"3005735","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme acetyl-CoA:alpha-glucosaminide acetyltransferase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIC","conceptCode":"C84899","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme acetyl-CoA:alpha-glucosaminide acetyltransferase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E725-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F1D7-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Acid lipase deficiency","valueDescription":"Wolman Disease","ValueMeaning":{"publicId":"3028409","version":"1","preferredName":"Wolman Disease","longName":"3028409","preferredDefinition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolman Disease","conceptCode":"C61271","definition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FAFB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F1EB-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Acid sphingomyelinase","valueDescription":"Niemann-Pick Disease","ValueMeaning":{"publicId":"3028411","version":"1","preferredName":"Niemann-Pick Disease","longName":"3028411","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease","conceptCode":"C61269","definition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FBBC-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F1FF-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Alpha-fucosidase deficiency","valueDescription":"Fucosidosis","ValueMeaning":{"publicId":"3028419","version":"1","preferredName":"Fucosidosis","longName":"3028419","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fucosidosis","conceptCode":"C61274","definition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCFE-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F213-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Alpha-L-iduronidase","valueDescription":"Hurler Syndrome","ValueMeaning":{"publicId":"3028416","version":"1","preferredName":"Hurler Syndrome","longName":"3028416","preferredDefinition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hurler Syndrome","conceptCode":"C61261","definition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC95-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F227-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Alpha-mannosidase B deficiency","valueDescription":"Alpha-Mannosidosis","ValueMeaning":{"publicId":"3028413","version":"1","preferredName":"Alpha-Mannosidosis","longName":"3028413","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by deficient activity of the enzyme alpha-D-mannosidase. There is a wide range of signs and symptoms including hepatomegaly, splenomegaly, hearing loss, respiratory infections, mental retardation, skeletal abnomalities, leveled nasal bridge and protuding forehead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Mannosidosis","conceptCode":"C84548","definition":"An autosomal recessive lysosomal storage disease characterized by deficient activity of the enzyme alpha-D-mannosidase. There is a wide range of signs and symptoms including hepatomegaly, splenomegaly, hearing loss, respiratory infections, mental retardation, skeletal abnormalities, leveled nasal bridge and protruding forehead.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC2C-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F23B-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Alpha-N-acetylglucosaminidase","valueDescription":"Mucopolysaccharidosis Type IIIB","ValueMeaning":{"publicId":"3005736","version":"1","preferredName":"Mucopolysaccharidosis Type IIIB","longName":"3005736","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetyl-alpha-D-glucosaminidase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIB","conceptCode":"C84898","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetyl-alpha-D-glucosaminidase. It is characterized by behavioral changes, sleep disturbances, and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E74A-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F24F-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Beta-galactosidase","valueDescription":"Mucopolysaccharidosis Type IVB","ValueMeaning":{"publicId":"3005742","version":"1","preferredName":"Mucopolysaccharidosis Type IVB","longName":"3005742","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta galactosidase. It is characterized by skeletal dysplasia and short stature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IVB","conceptCode":"C84902","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta galactosidase. It is characterized by skeletal dysplasia and short stature.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB86C79-20CF-52DA-E040-BB89AD436057","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F259-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Beta-glucuronidase","valueDescription":"Sly Syndrome","ValueMeaning":{"publicId":"3028420","version":"1","preferredName":"Sly Syndrome","longName":"3028420","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sly Syndrome","conceptCode":"C84903","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme beta-glucuronidase. It is characterized by hepatosplenomegaly, skeletal deformities, enlarged head, and mental retardation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD23-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F26D-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Glucocerebrosidase","valueDescription":"Gaucher Disease","ValueMeaning":{"publicId":"3028418","version":"1","preferredName":"Gaucher Disease","longName":"3028418","preferredDefinition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gaucher Disease","conceptCode":"C61268","definition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCDB-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F281-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Heparan N-sulfatase","valueDescription":"Mucopolysaccharidosis Type IIIA","ValueMeaning":{"publicId":"3005737","version":"1","preferredName":"Mucopolysaccharidosis Type IIIA","longName":"3005737","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme heparan sulfate sulfatase. It is characterized by behavioral changes, sleep disturbances, mental developmental delays and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIIA","conceptCode":"C84897","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme heparan sulfate sulfatase. It is characterized by behavioral changes, sleep disturbances, mental developmental delays and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E76F-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F28B-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Hypoxanthine-guanine phosphoribosyltransferase deficiency","valueDescription":"Lesch-Nyhan Syndrome","ValueMeaning":{"publicId":"3028414","version":"1","preferredName":"Lesch-Nyhan Syndrome","longName":"3028414","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesch-Nyhan Syndrome","conceptCode":"C61255","definition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC4F-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F29F-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Iduronate sulfatase","valueDescription":"Hunter Syndrome","ValueMeaning":{"publicId":"3028417","version":"1","preferredName":"Hunter Syndrome","longName":"3028417","preferredDefinition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hunter Syndrome","conceptCode":"C61260","definition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FCB8-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F2B3-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"N-acetylgalactosamine 4-sulfatase","valueDescription":"Maroteaux-Lamy Syndrome","ValueMeaning":{"publicId":"3028412","version":"1","preferredName":"Maroteaux-Lamy Syndrome","longName":"3028412","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maroteaux-Lamy Syndrome","conceptCode":"C61264","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FC07-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F2C7-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"N-acetylgalactosamine 6-sulfatase","valueDescription":"Mucopolysaccharidosis Type IVA","ValueMeaning":{"publicId":"3005743","version":"1","preferredName":"Mucopolysaccharidosis Type IVA","longName":"3005743","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IVA","conceptCode":"C84901","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB86C79-20F4-52DA-E040-BB89AD436057","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F2DB-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"N-acetylglucosamine 6-sulfatase","valueDescription":"Mucopolysaccharidosis Type IIID","ValueMeaning":{"publicId":"3005734","version":"1","preferredName":"Mucopolysaccharidosis Type IIID","longName":"3005734","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylglucosamine-6-sulfatase. It is characterized by behavioral changes, sleep disturbances and mental developmental delays.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis Type IIID","conceptCode":"C84900","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylglucosamine-6-sulfatase. It is characterized by behavioral changes, sleep disturbances and mental developmental delays.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EB83E85-E700-D623-E040-BB89AD434EBC","latestVersionIndicator":"Yes","beginDate":"2010-02-03","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F2E5-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"N-aspartyl-Beta-glucosaminidase","valueDescription":"Aspartylglycosaminuria","ValueMeaning":{"publicId":"3028421","version":"1","preferredName":"Aspartylglycosaminuria","longName":"3028421","preferredDefinition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartylglycosaminuria","conceptCode":"C61273","definition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FD46-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F30D-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Neuronal ceroid lipofuscinosis enzyme - NCL 1","valueDescription":"Infantile Neuronal Ceroid Lipofuscinosis","ValueMeaning":{"publicId":"3010915","version":"1","preferredName":"Infantile Neuronal Ceroid Lipofuscinosis","longName":"3010915","preferredDefinition":"A very rare form of neuronal ceroid lipofuscinosis inherited in an autosomal recessive pattern.  During the first six to eighteen months of life development is normal.  Subsequently, patients develop developmental abnormalities in speech and motor skills, blindness, epilepsy, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis Type 1","conceptCode":"C85861","definition":"A condition associated with mutation(s) in the PPT1 gene, encoding palmitoyl-protein thioesterase 1. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FC58647-700C-72A6-E040-BB89AD434C42","latestVersionIndicator":"Yes","beginDate":"2010-02-16","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F321-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"Neuronal ceroid lipofuscinosis enzyme - NCL 2: transpeptidase","valueDescription":"Late Infantile Neuronal Ceroid Lipofuscinosis","ValueMeaning":{"publicId":"3010914","version":"1","preferredName":"Late Infantile Neuronal Ceroid Lipofuscinosis","longName":"3010914","preferredDefinition":"Infantile neuronal ceroid lipofuscinosis in which the signs and symptoms appear later in life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis Type 2","conceptCode":"C85864","definition":"A condition associated with mutation(s) in the TPP1 gene, encoding tripeptidyl-peptidase- 1. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FC58647-6FE7-72A6-E040-BB89AD434C42","latestVersionIndicator":"Yes","beginDate":"2010-02-16","endDate":null,"createdBy":"WHITES","dateCreated":"2010-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B5D0F3B-F335-A584-E040-BB89AD4374CB","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","deletedIndicator":"No"},{"value":"N-acetylglucosamine-1-phosphotransferase","valueDescription":"I-Cell Disease","ValueMeaning":{"publicId":"3188499","version":"1","preferredName":"I-Cell Disease","longName":"3188499","preferredDefinition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"I-Cell Disease","conceptCode":"C61270","definition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B6858FA-72BE-8EA3-E040-BB89AD433118","latestVersionIndicator":"Yes","beginDate":"2011-02-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B6858FA-72D7-8EA3-E040-BB89AD433118","beginDate":"2010-03-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-02-03","modifiedBy":"ONEDATA","dateModified":"2011-02-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3188438","version":"1","preferredName":"Enzyme Deficiency Type","preferredDefinition":"A protein that speeds up chemical reactions in the body.:In medicine, a shortage of a substance (such as a vitamin or mineral) needed by the body.:Type; a subdivision of a particular kind of thing.","longName":"C16554:C94372:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzyme","conceptCode":"C16554","definition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Deficiency","conceptCode":"C94372","definition":"In medicine, a shortage of a substance (such as a vitamin or mineral) needed by the body.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B644B07-E2D2-1AA2-E040-BB89AD436C93","latestVersionIndicator":"Yes","beginDate":"2011-02-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-02-03","modifiedBy":"ONEDATA","dateModified":"2011-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228AACA-FAE4-E06A-E040-BB89AD437846","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2020-12-16","changeDescription":". 2020-12-16 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964919","version":"1","longName":"2138r1: Mucopolysaccharidosis and Other Storage Diseases Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"muc_post_enzym_eval_f100d","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalResult:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Indicate the enzyme that was","type":"Preferred Question Text","description":"Indicate the enzyme that was evaluated for activity level:","url":null,"context":"NHLBI"},{"name":"Indicate the enzyme that was evaluated for activity level","type":"Alternate Question Text","description":"Indicate the enzyme that was evaluated for activity level","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3028423","type":"BRIDG Mapping Path","description":"PerformedClinicalResult.Value(ANY=>CD) WHERE PerformedClinicalResult > PerformedObservation > DefinedObservation.nameCode = \"Determine Enzyme Activity Level Performed Enzyme Deficiency Type\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8228CE9C-5974-82B6-E040-BB89AD434105","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"WHITES","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2020-12-17","changeDescription":". 2020-12-17 ak Ok to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}